HER2-targeted therapies — a role beyond breast cancer
Do‐Youn Oh, Yung‐Jue Bang · Nature Reviews Clinical Oncology · 2019
Cited by 1,071 works. doi:10.1038/s41571-019-0268-3
Authors
References
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Comprehensive molecular portraits of human breast tumours
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
- Untangling the ErbB signalling network
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- Trastuzumab-Induced Hepatotoxicity: A Case Report
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer